published meta-analysis   sensitivity analysis   studies

convalescent plasma treatment in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsLibster, 2020 0.50 [0.09; 2.71] 0.50[0.09; 2.71]Libster, 202010%160NAnot evaluable clinical deteriorationdetailed resultsLibster, 2020 0.52 [0.29; 0.94] 0.52[0.29; 0.94]Libster, 202010%160NAnot evaluable ICU admissiondetailed resultsLibster, 2020 0.33 [0.07; 1.58] 0.33[0.07; 1.58]Libster, 202010%160NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-16 05:59 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 538,957 - roots T: 290